We manage the 'Criteria for the clinical use of immunoglobulin in Australia'. The criteria set out the conditions and circumstances for which the use of immunoglobulin (Ig) is clinically appropriate and can be considered under the national blood arrangements.

They list the medical conditions and circumstances for patients to access Ig products under the national blood arrangements.

Patients with a medical condition or circumstances not covered in the criteria may be able to access Ig privately or through a Jurisdictional Direct Order.

View the criteria(Opens in a new tab/window).

Read about how to use the criteria(Opens in a new tab/window).

The criteria help us direct Ig products to patients who:

  • are most likely to benefit from Ig therapy
  • have no other safe and effective alternative treatments.

Our criteria are vital to the Ig Governance Program. The program ensures we use our precious Ig resources carefully and that the use of Ig in Australia reflects:

  • appropriate clinical practice
  • current scientific evidence and expert advice
  • effective and ethical use of government money
  • relevant national safety and quality standards.

The criteria are based on published scientific evidence and the opinions of clinical experts. These include individuals, clinical colleges and clinical societies.

The criteria are not intended to be clinical practice guidelines. They identify the conditions and circumstances for which:

  • the use of Ig products is clinically appropriate
  • Ig products can be accessed under the national blood arrangements.

Medical officers and transfusion medicine professionals can use the criteria to identify patients who may be eligible to receive government-funded Ig products under the national blood arrangements. All requests for Ig products are assessed against the criteria.

Learn more about Ig products.

Updating our criteria

In keeping with an evidence-based approach, we regularly review our criteria to ensure they reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.

We updated our criteria as a whole in 2018. Since then, we have been working on a rolling review process to update relevant components of the criteria following a review of evidence. These updates are published here on our website.

Updates since 2018

Since 2018, we've made changes to the criteria. Search for changes made by medical condition under the relevant specialty:

Get in touch

For more information about the criteria, contact us.

Phone: 1300 025 663 (13 000 BLOOD)

Email: IgGovernance@blood.gov.au

Last updated: 27 Mar 2024

Back to top